WO2006024689A1 - Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency - Google Patents
Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency Download PDFInfo
- Publication number
- WO2006024689A1 WO2006024689A1 PCT/FI2005/000333 FI2005000333W WO2006024689A1 WO 2006024689 A1 WO2006024689 A1 WO 2006024689A1 FI 2005000333 W FI2005000333 W FI 2005000333W WO 2006024689 A1 WO2006024689 A1 WO 2006024689A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- testosterone
- hypogonadism
- syndrome
- deficiency
- estrogen receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Definitions
- This invention relates to a method for treatment or prevention of androgen deficiency in a male individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator (SERM).
- SERM selective estrogen receptor modulator
- the invention concerns further methods for treatment or prevention of diseases or disorders caused by said androgen deficiency.
- Masculine sex hormones are responsible for the development of the masculine sex characteristics. Furthermore, they are required for reproduction.
- the main element of the androgens is testosterone, which is imperative for the development and the function of the internal and external masculine sex organs, which has a supportive influence regarding muscle growth, which determines the distribution and the density of hair growth, which has a positive influence with respect to the production of erythrocytes and with respect to the distribution of erythropoietin and the cognitive functions.
- a shortage of testosterone may be classified into two principle forms, which are designated primary and secondary hypogonadism. Diseases based on testosterone shortage include for instance osteoporosis, muscle atrophy, senescence outfall symptoms,
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005279178A AU2005279178A1 (en) | 2004-09-03 | 2005-07-20 | Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency |
CA002578852A CA2578852A1 (en) | 2004-09-03 | 2005-07-20 | Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency |
MX2007002606A MX2007002606A (en) | 2004-09-03 | 2005-07-20 | Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency. |
JP2007529372A JP2008511615A (en) | 2004-09-03 | 2005-07-20 | Estrogen receptor selective modulator for use in the manufacture of a pharmaceutical preparation for use in the treatment or prevention of androgen deficiency |
EP05771627A EP1786408A4 (en) | 2004-09-03 | 2005-07-20 | Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency |
BRPI0514701-8A BRPI0514701A (en) | 2004-09-03 | 2005-07-20 | use of a selective estrogen receptor modulator, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof |
NO20071160A NO20071160L (en) | 2004-09-03 | 2007-03-01 | Use of a selective estrogen receptor modulator for the preparation of a pharmaceutical composition for use in a method for the treatment or prevention of androgen deficiency |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60690704P | 2004-09-03 | 2004-09-03 | |
US60/606,907 | 2004-09-03 | ||
FI20041216 | 2004-09-21 | ||
FI20041216A FI20041216A0 (en) | 2004-09-21 | 2004-09-21 | A method of treating or preventing an androgen deficiency |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006024689A1 true WO2006024689A1 (en) | 2006-03-09 |
Family
ID=35999733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FI2005/000333 WO2006024689A1 (en) | 2004-09-03 | 2005-07-20 | Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1786408A4 (en) |
JP (1) | JP2008511615A (en) |
KR (1) | KR20070059110A (en) |
AU (1) | AU2005279178A1 (en) |
BR (1) | BRPI0514701A (en) |
CA (1) | CA2578852A1 (en) |
MX (1) | MX2007002606A (en) |
NO (1) | NO20071160L (en) |
RU (1) | RU2007112114A (en) |
WO (1) | WO2006024689A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2518039A1 (en) | 2007-02-14 | 2012-10-31 | Hormos Medical Ltd. | Method for the preparation of therapeutically valuable triphenylbutene derivatives |
US20130217696A1 (en) * | 2007-06-13 | 2013-08-22 | Quatrx Pharmaceuticals Company | Methods for the treatment of erectile dysfunction using fispemifene |
US9078871B2 (en) | 2010-06-10 | 2015-07-14 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
WO2015135061A1 (en) | 2014-03-10 | 2015-09-17 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm |
US9187460B2 (en) | 2011-12-14 | 2015-11-17 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
WO2016108172A1 (en) | 2014-12-29 | 2016-07-07 | Olon S.P.A. | Process for the preparation of ospemifene and fispemifene |
WO2023175010A1 (en) * | 2022-03-15 | 2023-09-21 | Centre D'etude Des Cellules Souches (Cecs) | Use of bazedoxifene for increasing muscle survival |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0793961A1 (en) * | 1996-02-28 | 1997-09-10 | Pfizer Inc. | Use of droloxifene for the manufacture of a medicament for increasing serum levels of testosterone |
WO2001036360A1 (en) * | 1999-11-16 | 2001-05-25 | Hormos Medical Corporation | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
WO2001091744A1 (en) * | 2000-05-26 | 2001-12-06 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
US6512002B2 (en) * | 2000-01-12 | 2003-01-28 | Pfizer Inc. | Methods of treatment for premature ejaculation in a male |
WO2003047504A2 (en) * | 2001-11-29 | 2003-06-12 | Gtx Inc. | Prevention and treatment of androgen-deprivation induced osteoporosis |
WO2003072092A1 (en) * | 2002-02-21 | 2003-09-04 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
US6632447B1 (en) * | 1998-05-07 | 2003-10-14 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
-
2005
- 2005-07-20 RU RU2007112114/15A patent/RU2007112114A/en not_active Application Discontinuation
- 2005-07-20 JP JP2007529372A patent/JP2008511615A/en not_active Abandoned
- 2005-07-20 MX MX2007002606A patent/MX2007002606A/en unknown
- 2005-07-20 EP EP05771627A patent/EP1786408A4/en not_active Withdrawn
- 2005-07-20 CA CA002578852A patent/CA2578852A1/en not_active Abandoned
- 2005-07-20 WO PCT/FI2005/000333 patent/WO2006024689A1/en active Application Filing
- 2005-07-20 KR KR1020077006922A patent/KR20070059110A/en not_active Application Discontinuation
- 2005-07-20 BR BRPI0514701-8A patent/BRPI0514701A/en not_active IP Right Cessation
- 2005-07-20 AU AU2005279178A patent/AU2005279178A1/en not_active Abandoned
-
2007
- 2007-03-01 NO NO20071160A patent/NO20071160L/en not_active Application Discontinuation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0793961A1 (en) * | 1996-02-28 | 1997-09-10 | Pfizer Inc. | Use of droloxifene for the manufacture of a medicament for increasing serum levels of testosterone |
US6632447B1 (en) * | 1998-05-07 | 2003-10-14 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
WO2001036360A1 (en) * | 1999-11-16 | 2001-05-25 | Hormos Medical Corporation | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
US6512002B2 (en) * | 2000-01-12 | 2003-01-28 | Pfizer Inc. | Methods of treatment for premature ejaculation in a male |
US20030114440A1 (en) * | 2000-01-12 | 2003-06-19 | Lee Andrew G. | Compositions and methods of treatment for conditions responsive to testosterone elevation |
WO2001091744A1 (en) * | 2000-05-26 | 2001-12-06 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
WO2003047504A2 (en) * | 2001-11-29 | 2003-06-12 | Gtx Inc. | Prevention and treatment of androgen-deprivation induced osteoporosis |
WO2003072092A1 (en) * | 2002-02-21 | 2003-09-04 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
Non-Patent Citations (5)
Title |
---|
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 133:26826, KE H.Z. ET AL: "Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat" XP003010330 * |
DATABASE BIOSIS [online] STEINER M.S. ET AL: "Selective estrogen receptor modulators for the chemoprevention of prostate cancer", XP003010322, Database accession no. (prev200100240383) * |
ENDOCRINOLOGY, vol. 141, no. 4, 2000, pages 1338 - 1344 * |
See also references of EP1786408A4 * |
UROLOGY, vol. 57, no. 4A, April 2001 (2001-04-01), pages 68 - 72 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2518039A1 (en) | 2007-02-14 | 2012-10-31 | Hormos Medical Ltd. | Method for the preparation of therapeutically valuable triphenylbutene derivatives |
EP2821385A2 (en) | 2007-02-14 | 2015-01-07 | Hormos Medical Ltd. | Method for the preparation of therapeutically valuable triphenylbutene derivatives |
US20130217696A1 (en) * | 2007-06-13 | 2013-08-22 | Quatrx Pharmaceuticals Company | Methods for the treatment of erectile dysfunction using fispemifene |
US10500166B2 (en) * | 2007-06-13 | 2019-12-10 | Quatrx Pharmaceuticals | Methods for the treatment of erectile dysfunction using fispemifene |
US9078871B2 (en) | 2010-06-10 | 2015-07-14 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
US9193714B2 (en) | 2011-12-14 | 2015-11-24 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
US9187460B2 (en) | 2011-12-14 | 2015-11-17 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
EP3116510A4 (en) * | 2014-03-10 | 2017-08-16 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm |
US9744177B2 (en) | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
WO2015135061A1 (en) | 2014-03-10 | 2015-09-17 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm |
US10548903B2 (en) | 2014-03-10 | 2020-02-04 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
WO2016108172A1 (en) | 2014-12-29 | 2016-07-07 | Olon S.P.A. | Process for the preparation of ospemifene and fispemifene |
WO2023175010A1 (en) * | 2022-03-15 | 2023-09-21 | Centre D'etude Des Cellules Souches (Cecs) | Use of bazedoxifene for increasing muscle survival |
Also Published As
Publication number | Publication date |
---|---|
JP2008511615A (en) | 2008-04-17 |
AU2005279178A1 (en) | 2006-03-09 |
BRPI0514701A (en) | 2008-06-24 |
EP1786408A1 (en) | 2007-05-23 |
MX2007002606A (en) | 2007-05-15 |
NO20071160L (en) | 2007-05-25 |
RU2007112114A (en) | 2008-10-10 |
CA2578852A1 (en) | 2006-03-09 |
EP1786408A4 (en) | 2010-07-28 |
KR20070059110A (en) | 2007-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Begam et al. | Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review | |
Komm et al. | An overview of current and emerging SERMs | |
WO2006024689A1 (en) | Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency | |
EP2106212B1 (en) | Nuclear receptor binding agents | |
Suh et al. | Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer | |
US9561238B2 (en) | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy | |
FI118755B (en) | Triphenylethylenes for use in the prevention and treatment of osteoporosis | |
KR101403893B1 (en) | New uses for 4,17β-dihydroxyandrost-4-ene-3-one | |
US20060293294A1 (en) | Method for treatment or prevention of androgen deficiency | |
EP2819676B1 (en) | Combination therapy for treating androgen deficiency | |
Berga | Profile of ospemifene in the breast | |
Bojkova et al. | Metformin in chemically-induced mammary carcinogenesis in rats | |
JP6025301B2 (en) | C-19 steroids for therapeutic use | |
Clarke et al. | New selective estrogen and androgen receptor modulators | |
Ray et al. | Development of estrogen antagonists as pharmaceutical agents | |
MX2007000741A (en) | Compositions comprising 5-alpha reductase inhibitors, and serms and methods of use thereof. | |
Wardley | FULVESTRANT: A REVIEW OF ITS DEVELOPMENT, PRE‐CLINICAL AND CLINICAL DATA | |
CN1168448C (en) | Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor | |
CN1893955A (en) | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases | |
JP2001505574A (en) | Method for preventing neurodegeneration and cognitive dysfunction using 17α-dihydroequilenin | |
Levin | Fulvestrant | |
Kumar et al. | Antiestrogen therapy for Breast Cancer: An overview. | |
US20230210870A1 (en) | Methods of treating female health conditions related to sex hormones | |
Sorbera et al. | Pipendoxifene | |
Laugier et al. | Dissociated effects of tamoxifen on growth and on progesterone receptor induction in quail oviduct |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200580029252.6 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005279178 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/002606 Country of ref document: MX Ref document number: 2578852 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007529372 Country of ref document: JP Ref document number: 927/CHENP/2007 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005771627 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005279178 Country of ref document: AU Date of ref document: 20050720 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005279178 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077006922 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007112114 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005771627 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0514701 Country of ref document: BR |